glp 1 and vision Lipsitz, Ponterio & Comerford Frontiers | Unlocking the potential
Description
Eli Lilly CEO David Ricks announces details of the Medicare GLP-1 bridge program, offering weight loss medications like Fondeo and Zepbound for $50 per month to 20 million eligible Medicare Part D patients starting July 1.

in patients with knee osteoarthritis and type 2 diabetes if treatment is sustained for a sufficient period, according to data.The researchers, who published their findings in the Annals of the Rheumatic Diseases, added that the result may be mediated by weight loss.

Led by Dr

Rationale Obesity remains a major global health challenge, severely affecting metabolic and cardiovascular health

Triple-agonist peptide
Composite kidney events were reported in 134 (38.2%) and 393 (44.2%) patients in the GLP-1RA and DPP-4i groups, respectively (subdistribution HR 0.72, 95% CI 0.560.93)
